- Exchanges
- BSE, NSE
- Industry
- Pharmaceuticals
- Issue
- Book building
Supriya Lifescience IPO
₹390.85
+42.65% on listing
Listing-day close · NSE · 28 Dec 2021 · issue price ₹274
Supriya Lifescience’s ₹700 crore IPO was priced at ₹274 a share. It listed on the NSE on 28 Dec 2021 and closed its first day at ₹390.85, up 42.65% on the issue price.
Timeline
- Opens
- Closes
- Allotment
- Refunds
- Shares in demat
- Listing
Issue details
- Issue size
- ₹700 Cr
- Fresh issue
- ₹200 Cr
- Offer for sale
- ₹500 Cr
- Lot size
- 54 shares
- Minimum investment
- ₹14,796
- Face value
- ₹2
- Registrar
- MUFG Intime India
Subscription
| Category | Shares offered | Times subscribed |
|---|---|---|
| Total | — | 39.68× |
Overall, from the basis of allotment.
Financials and valuation
- Market cap (post-issue)
- ₹700 Cr
- Promoter holding
- 99.98% → 68.24%
From the offer documents.
Listing
- Listing date
- 28 Dec 2021
- Issue price
- ₹274
- Open
- ₹421.00
- High
- ₹421.00
- Low
- ₹383.20
- Close
- ₹390.85
Listing day on the NSE. The close was +42.65% on the issue price.
SUPRIYA share price todayFAQs
When did the Supriya Lifescience IPO open and close?
It opened on 16 Dec 2021 and closed on 20 Dec 2021.
What was the Supriya Lifescience IPO price?
The price band was ₹265–274 a share. The final issue price was ₹274.
What is the lot size and minimum investment?
One lot is 54 shares, ₹14,796 at ₹274 a share. Retail investors apply in whole lots.
How much did Supriya Lifescience raise?
₹700 crore: ₹200 crore of new shares and ₹500 crore offered by existing shareholders.
How many times was the Supriya Lifescience IPO subscribed?
39.68 times overall.
How did Supriya Lifescience list?
It listed on the NSE on 28 Dec 2021 at ₹421.00 and closed the day at ₹390.85, up 42.65% on the ₹274 issue price.
Who is the registrar of the Supriya Lifescience IPO?
MUFG Intime India handles the allotment, refunds and credit of shares.
For information only. Not investment advice or a research report.
Full disclaimerSee how an IPO fits your plan
Armor checks every holding against your goals, risk and timeline.
Get the app